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Summary
OBJECTIVE: To assess the prognostic value of various
parameters including positron emission tomography / com-
puted tomography (PET/CT) and identify risk factors for
survival of patients with non-Hodgkin’s lymphoma (NHL)
and Hodgkin’s lymphoma (HL) treated with autologous
stem cell transplantation (ASCT).
METHODS: Patient charts and our prospective ASCT
database were assessed for the impact of documented vari-
ables on event free survival (EFS) and overall survival
(OS), including salvage and conditioning regimens used,
and PET/CT results before and after ASCT.
RESULTS: Overall, 180 patients with NHL (n = 134; 74%)
or HL (n = 46; 26%) received ASCT from December 2000
to May 2011. Of the NHL patients, 59 (44%) had diffuse
large B-cell lymphoma (DLBCL). Conditioning was
mainly performed with cyclophosphamide, carmustine,
etoposide (CBV) (n = 72; 40%) or carmustine, etoposide,
cytarabine, melphalan (BEAM) (n = 103; 57%).
Treatment-related mortality (TRM) was 1.7%. Outcome
data are in line with previously reported studies, especially
the data for salvage treatment and BEAM conditioning in
DLBCL patients confirmed the outcome reported recently
in a phase III study. Positive pre- and post-transplanta-
tion PET/CT was an adverse risk factor for survival (PET/
CT+ before ASCT: hazard ratio (HR): 2.65 (1.11−6.33),
p = 0.029; PET/CT+ after ASCT: HR: 7.11 (2.76−18.34),
p <0.0001). Other risk factors for survival were primary re-
fractory disease, initial lymphoma stage, number of pre-
vious chemotherapy lines, and high amounts of blood
product transfusions.
CONCLUSIONS: Conditioning with CBV or BEAM and
subsequent ASCT was feasible and effective. Initial lymph-
oma stage and number of previous treatment lines were
identified as independent risk factors for EFS in DLBCL
and HL patients.
List of abbreviations
ASCT autologous stem cell transplantation
BEAM conditioning regimen with carmustine, etoposide, cytarabine
and melphalan
BMI body mass index
CBV conditioning regimen with cyclophosphamide, carmustine and
etoposide
CD34 cluster of differentiation 34
CHOP first-line regimen with prednisone, cyclophosphamide,
doxorubicin and vincristine
CI confidence interval
CLL chronic lymphocytic leukaemia
CNS central nervous system
CORAL Collaborative Trial in Relapsed Aggressive Lymphoma
CR complete remission
CRu complete remission unconfirmed
Dexa-BEAM salvage regimen with dexamethasone, carmustine,
etoposide, cytarabine and melphalan
DHAP salvage regimen with dexamethasone, cytarabine and
cisplatin
DLBCL diffuse large B-cell lymphoma
DMSO dimethyl sulfoxide
EFS event free survival
EPOCH salvage regimen with prednisone, doxorubicin, vincristine,
etoposide and cyclophosphamide
FDG Fluorodeoxyglucose
FL follicular lymphoma
G-CSF granulocyte-colony stimulating factor
HDC high dose chemotherapy
HL Hodgkin’s lymphoma
HR hazard ratio
ICE salvage regimen with ifosfamide, carboplatin and etoposide
MCL mantle cell lymphoma
NHL Non-Hodgkin’s lymphoma
OS overall survival
PET/CT positron emission tomography/computed tomography
PD progressive disease
PR partial remission
RBC red blood cells
SD stable disease
TCL T cell lymphoma
TRM treatment related mortality
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Introduction
High-dose chemotherapy (HDC) followed by autologous
stem cell transplantation (ASCT) is being widely used as
salvage treatment in patients with non-Hodgkin’s lymph-
oma (NHL) or Hodgkin’s lymphoma (HL) [1–3]. This
treatment strategy has the potential to improve significantly
survival compared with standard dosed salvage chemother-
apy alone. It offers a chance for a cure in up to 50% of
patients with chemosensitive relapse, while the results are
still unsatisfactory in patients with primary refractory dis-
ease, where a cure rate of 10%–25% may be achieved [4,
5]; an important prognostic factor for survival is the re-
sponse to salvage chemotherapy. Patients with complete re-
mission (CR) before ASCT have a better survival than pa-
tients with partial remission (PR) [6, 7]. In addition, many
centres offer HDC and ASCT also as consolidation treat-
ment after first line therapy to patients with poor prognostic
features, i.e., in patients with T cell lymphoma or primary
central nervous system lymphoma. The autologous stem
cell transplantation programme Zurich includes two hos-
pitals, the University Hospital and the Triemli City Hos-
pital. It was initiated in 1988, and we reported first res-
ults 11 years later after having performed more than 250
ASCTs, predominantly in patients with NHL, HL, multiple
myeloma and germ cell tumours [8]. Recently, we reported
our current results in patients with multiple myeloma, who
received ASCT as consolidation treatment. Beside surviv-
al data comparable to published data, we observed minim-
al toxicity and a low treatment related mortality (TRM) of
0.5% [9].
Treatment modalities for HL and NHL have changed dur-
ing the last 10 years owing to various improvements in this
field; the possibility of harvesting peripheral blood stem
cells omits the invasive bone marrow harvest procedure.
The use of granulocyte-colony stimulating factors (G-CSF)
reduces the time to engraftment and, thus, the risk of in-
fectious complications during neutropenia [10, 11]. Patient
management has also improved through implementation
and continuous adjustment of international standard oper-
ating procedures. We retrospectively analysed the clinical
course and the outcome of all patients with NHL and HL
undergoing ASCT from December 2000 until May 2011 to
identify possible risk factors for survival and to control for
quality in comparison to published data. Further, we placed
a special emphasis on the prognostic impact of positron
emission tomography / computed tomography (PET/CT)
before and after ASCT on treatment outcome.
Patients and methods
Patient data assessment
Patients with NHL and HL who received an ASCT at our
transplantation centre were analysed retrospectively, based
on a prospective transplantation database. This analysis
was approved by our local ethics committee.
Data regarding lymphoma stage, the salvage and condition-
ing regimens used, the response to treatment before and
after ASCT, event free survival (EFS) and overall survival
(OS) were collected. Additional variables like age, gender,
body mass index (BMI), the amount of cluster of differen-
tiation (CD) 34 positive cells mobilised, and PET/CT res-
ults were documented. We also collected data regarding the
haematological toxicity and the supportive care of the pa-
tients during the post-transplant phase.
Treatment
All patients received primary salvage chemotherapy as
chosen by the attending oncologists. Salvage regimens
used were ICE (ifosfamide, carboplatin, etoposide), DHAP
(dexamethasone, cytarabine, cisplatin), EPOCH (pred-
nisone, doxorubicine, vincristine, etoposide, cyclophosph-
amide), Dexa-BEAM (dexamethasone, carmustine, etopos-
ide, cytarabine, melphalan) or CHOP-like (prednisone,
cyclophosphamide, doxorubicin, vincristine) regimens.
Stem cell mobilisation was usually performed after the
second or third treatment cycle by administering daily fil-
grastim at a dose of 10 μg/kg body weight from day -3 on.
Apheresis was performed at our transplantation centre until
at least 2 x 106 CD34+ cells per kilogramme body weight
were collected. Purging was not part of the procedure. The
collected cell products were cryopreserved with 10% di-
methyl sulfoxide (DMSO) and stored in liquid nitrogen un-
til the day of ASCT. Cell thawing was performed immedi-
ately before retransfusion in a 37 °C water bath.
Conditioning chemotherapy consisted mainly of BEAM
(carmustine 200–300 mg/m2, melphalan 140 mg/m2,
etoposide 8 x 100–150 mg/m2, and cytarabine 8 x 200
mg/m2) or CBV (cyclophosphamide 4 x 1500 mg/m2,
etoposide 6 x 100–150 mg/m2, and carmustine 200–300
mg/m2). Patients with poor performance status, organ dys-
functions like renal insufficiency, reduced pulmonary dif-
fusion capacity or age over 65 years could receive a re-
duced dose of etoposide and/ or carmustine after discussion
in our multidisciplinary transplantation board. As previ-
ously reported patients received daily filgrastim at a dose
of 5 μg/kg body weight from day +5 on or pegfilgrastim 6
mg once on day +1 after ASCT to shorten time to engraft-
ment [12].
Regarding the management of febrile neutropenia after
ASCT, we comply with general European guidelines at our
centre [13]. Briefly, patients received empiric broad spec-
trum antibiotic therapy with Pseudomonas-active β-lactam
agents (like piperacillin-tazobactam or cefepime in first,
carbapenems in second line). In case of obvious infections
with gram-positive germs (i.e., catheter-infection) the pa-
tients also received vancomycin. According to internation-
al guidelines, the transfusion threshold after ASCT for pa-
tients with anaemia was haemoglobin of 7 g/dl (or higher
in case of associated symptoms or cardiovascular disease),
and for patients with thrombocytopenia thrombocyte levels
of 10 x 109 /L (20 x 109 /L for patients with increased risk
of bleeding) [14, 15].
Response criteria
Assessment of disease response was based on every avail-
able clinical or radiological evaluation, including PET/CT,
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as documented in the patient charts and the radiologic re-
ports. Because of the low patient numbers, we only dis-
criminated between patients with CR or unconfirmed CR
(CRu), and patients with less than CR.
EFS was defined as time from ASCT to the time of first re-
currence after achievement of CR or to the time of progres-
sion in patients with unconfirmed CR, as verified by clinic-
al examination, imaging and biopsy, or to the time of death
by any cause. OS was defined as time from ASCT to the
time of death by any cause, as documented in the patient
charts.
Assessment of PET-response
2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG)-PET
imaging data were acquired on a combined PET/CT in-
line system (Discovery LS, RX or Discovery STE; GE
Health Systems, Milwaukee, WI). This technique allowed
the combination of CT-scans and PET images in a single
session. PET/CT was available since 2001 at our institu-
tion, and has been increasingly used for staging and treat-
ment monitoring of lymphoma patients during and after
end of treatment. It was used individually at the treating
physician’s discretion, and therefore PET data are not
available for all patients. PET/CT scans performed during
or after completion of salvage chemotherapy (pre-ASCT
PET/CT) and within three months after ASCT (post-ASCT
PET/CT) were evaluated. Image analysis was routinely car-
ried out by two nuclear radiology physicians in consensus.
PET/CT scans were assessed for residual pathologic FDG-
uptake.
Statistics
Descriptive statistics (median and range, or counts) were
calculated for all variables. Event free and overall survival
were calculated from the date of ASCT, and censored at the
date of last follow-up. Survival curves were computed us-
Table 1: Patient characteristics.
Parameter Patients N = 180 (100%)
Age
<65 years – no. (%)
≥65 years – no. (%)
Median – yr
Range – yr
163 (91)
17 (9)
53
18.7–67.9
Gender
Male – no. (%)
Female – no. (%)
117 (65)
63 (35)
BMI before ASCT
Median – kg/m²
Range – kg/m²
24.9
16.2–45.7
Lymphoma type and NHL subtypes
Non-Hodgkin’s lymphoma – no. (%)
– Follicular lymphoma – no. (%)
– Chronic lymphocytic leukaemia – no.(%)
– Marginal zone lymphoma – no. (%)
– DLBCL – no. (%)
– Mantle cell lymphoma – no. (%)
– T-cell lymphoma – no. (%)
– Other – no. (%)
Hodgkin’s lymphoma – no. (%)
134 (74)
18 (10)
1 (0.5)
1 (0.5)
59 (32)
25 (14)
25 (14)
5 (3)
46 (26)
Remission status before ASCT
CR/CRu
Less than CR
78 (43)
94 (52)
ASCT indication
Primary refractory disease
Relapse (>3 months after 1st line treatment)
Consolidation
41 (23)
117 (65)
22 (12)
PET/CT for clinical monitoring
Before ASCT – no. (%)
After ASCT – no. (%)
87 (48)
63 (35)
First line treatment – no. (%)
CHOP +/– rituximab
CHOEP +/– rituximab
Hyper-CVAD +/– rituximab
ABVD-like
BEACOPP
Other
106 (59)
8 (4.5)
6 (3.5)
36 (20)
9 (5)
15 (8)
Number of previous treatment lines - median (range)
Non-Hodgkin’s lymphoma
– Low-grade lymphoma
– DLBCL
– Mantle cell lymphoma
– T-cell lymphoma
Hodgkin’s lymphoma
2 (1–5)
2 (1–5)
2 (1–9)
2 (1–3)
2 (2–4)
BMI = body mass index; ASCT = autologous stem cell transplantation. NHL = non-Hodgkin’s lymphoma; DLBCL = diffuse large B-cell lymphoma;
PET/CT = positron emission tomography / computed tomography.
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ing the method of Kaplan and Meier, and compared using
the log-rank test [16]. Risk factor analysis for survival was
performed by univariate Cox proportional hazards models
and multivariate Cox regression models. P-values <0.05
were considered statistically significant. All analyses were
performed in the R programming language [17].
Results
Patient demographics
Between December 2000 and May 2011, a total of 180
consecutive ASCTs were performed in lymphoma patients
at our centre. Of these patients, 59 (32%) were diagnosed
with diffuse large B-cell lymphoma (DLBCL) and 46
(26%) with HL. About two-thirds were male (65%) and
Figure 1
Correlation of the number of reinfused CD34+ stem cells with the
length of neutropenias (r = –0.25, fig. A) and thrombocytopenias (r
= –0.18, fig. B) after ASCT.
one-third female (35%). Eighty-seven (48%) received a
PET/CT during or after salvage chemotherapy, and 63
(35%) also received PET/CT within 3 months after ASCT.
In our patient cohort, 15% of DLBCL patients had received
prior rituximab during previous treatment until 2006, while
from 2007 on 93% of the DLBCL patients had already
been pretreated with rituximab. Some of the patients had
received first-line therapy at other hospitals or at oncolo-
gical private practices before they were subsequently re-
ferred to our transplantation centre for salvage treatment
and ASCT. The main patient characteristics are shown in
table 1.
Treatment period
All clinical data is shown in table 2. Patients with HL re-
ceived predominantly EPOCH (n = 19, 41%) or DHAP (n =
19, 41%) as salvage chemotherapy, while DLBCL patients
received predominantly ICE (n = 31, 53%) or EPOCH (n =
17, 29%) combined with rituximab.
The conditioning regimens mainly used were BEAM (n =
103; 57%) and CBV (n = 72; 40%). Five patients (3%)
received other conditioning regimens. The use of condi-
tioning regimen according to the lymphoma subtypes is
presented in table 3. Patients received subsequently a min-
imum of 1.96 x 106 CD34+ stem cells per kilogramme of
body weight (median 4.1 x 106 CD34+ cells; range, 1.96
x 106–20.1 x 106). The median duration of grade 4 neut-
ropenia and the median time to engraftment were 8 days
(range, 5–22 days) and 9 days (range, 7–23 days), respect-
ively. The median duration of grade 4 thrombocytopenia
was 6 days (range, 0–20 days). The number of CD34+
Table 2: Conditioning and post-ASCT variables.
Parameter (n = 180 patients) Value
Conditioning regimen
CBV – no. (%)
BEAM – no. (%)
Other – no. (%)
72 (40)
103 (57)
5 (3)
CD 34+ cells reinfused
Median – x106 cells /kg of body weight
Range – x106 cells /kg of body weight
4.1
1.96–20.1
Duration grade 4 neutropenia, median (range) – days
– after CBV conditioning, median (range) – days
– after BEAM conditioning, median (range) – days
8 (5–22)
9 (5–14)
8 (5–22)
Duration grade 4 thrombopenia, median (range) - days
– after CBV conditioning, median (range) – days
– after BEAM conditioning, median (range) – days
6 (0–20)
6 (0–19)
6 (0–20)
Duration of filgrastim treatment:
Median – days
Range – days
6
0–16
Occurrence of neutropenic fever – no. (%)
Use of antibiotics – no. (%)
Use of fungistatics – no. (%)
160 (89)
169 (94)
116 (64)
Platelet transfusions
Median – no. of transfusions
Range – no. of transfusions
2
0–60
Red blood cell transfusions
Median – no. of transfusions
Range – no. of transfusions
2
0–43
Hospital stay from day of ASCT
Median – days
Range – days
15
9–72
Treatment related mortality, overall – no. (%) 3 (1.7)
CD = cluster of differentiation; ASCT = autologous stem cell transplantation; TRM = treatment related mortality; CBV = cyclophosphamide,
carmustine and etoposide; BEAM = carmustine, etoposide, cytarabine and melphalan.
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stem cells correlated inversely with the duration of grade
4 thrombocytopenia (correlation coefficient r = –0.1815)
and the duration of grade 4 neutropenia (r = –0.2502) (fig.
1a, b). The median length of hospital stay from the day of
ASCT was 15 days (range, 9–72 days). Patients received
a median of 2 units (range, 0–60) platelet transfusions and
a median of 2 units (range, 0–43) red blood cell (RBC)
transfusions during hospital stay. Fever developed in 160
(89%) patients after ASCT, and the use of antibiotics for
therapeutic purposes was necessary in 169 (94%) patients
during the post-transplant period. Bacterial pathogens were
isolated in 46 (26%) patients. Infectious agents most com-
monly isolated were Klebsiella pneumoniae (n = 6; 3%),
Escherichia coli (n = 10; 6%) and coagulase-negative Sta-
phylococcus sp. (n = 13; 7%).
Four (2%) patients died within the first 100 days after
ASCT. One patient died due to disease progression, and
the other three patients died due to infectious complica-
tions: one Pseudomonas aeruginosa septicaemia, one cyto-
megalovirus pneumonitis, and one Aspergillus fumigatus
pneumonia. The TRM for the whole patient collective was
1.7%.
Figure 2
Event free survival (A) and overall survival (B) of the patients with
respect to the different lymphoma subgroups.
MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell
lymphoma; HL, Hodgkin’s lymphoma; TCL, T cell lymphoma.
Survival
Sufficient follow-up data was available for all patients ex-
cept for one female patient, who was lost 53 days after
ASCT. She was from abroad and came to Switzerland only
for the ASCT procedure. The median follow-up was 31
months (range, 0.29–136 months). The median EFS and
OS were not reached until the end of follow-up for the
whole patient collective. OS differed between patients with
DLBCL, HL, mantle cell lymphoma (MCL), follicular
lymphoma (FL) and T-cell lymphoma (TCL) significantly
(p <0.001). TCL patients had a worse prognosis compared
with the other lymphoma subtypes. No statistically signi-
ficant differences were seen regarding EFS (fig. 2a, b). The
3-year EFS was 67% for HL patients treated with CBV pre-
dominantly from 2000 to 2005, and 65% for HL patients
treated with BEAM as conditioning regimen from 2006 on.
The corresponding 3-year OS were 88% and 82%, respect-
ively. No differences were seen in HL patients treated in
the late period with BEAM compared with the early peri-
od with CBV regarding initial lymphoma stage, length of
CR before relapse or patient age. For DLBCL patients,
3-year EFS was 76% in the early period, and 27% in the
late period. The corresponding 3-year OS were 76% and
54%, respectively. The patients with DLBCL treated dur-
ing the early period with CBV tended to be younger than
Figure 3
Impact of chemosensitivity to primary chemotherapy on event free
survival (A) and overall survival (B).
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the DLBCL patients treated later with BEAM, although the
difference did not reach statistical significance (p = 0.052).
Patients with primary refractory disease had a statistically
worse EFS and OS than patients with a relapse after re-
sponse to initial treatment (3-year EFS 37% versus 63%, p
= 0.0008; 3-year OS 55% versus 76%; p = 0.003) (fig. 3a,
b). In contrast, no statistically significant survival differ-
ences were seen regarding the disease status before ASCT
(CR/CRu versus less than CR: 3-year EFS 60% versus
51%, p = 0.12; 3-year OS 72% versus 69%, p = 0.58). Also
no statistically significant differences were seen with re-
gard to the duration of remission before relapse or the use
of rituximab during salvage treatment.
Response assessment with PET/CT and decisional
impact
Overall, 39 (45%) of 87 patients with pre-ASCT PET/CT
had residual FDG-uptake considered pathological. Patients
with partial remission continued with their scheduled pro-
cedure, while patients with no response or progressive dis-
ease received a new non-crossresistant salvage treatment.
Twenty (32%) of 63 patients with post-ASCT PET/CT had
residual FDG-uptake considered pathological. As a con-
sequence, six patients received short-term follow-up with
PET/CT within 3 months, four patients immediately re-
ceived new chemotherapy, and three patients received ra-
diotherapy. One additional patient was planned for radio-
therapy but died as a result of lymphoma progression be-
fore treatment could be initiated. Two patients had a biopsy
that was negative, and one patient underwent a splenec-
tomy. In three patients the positive post-ASCT PET/CT had
no impact on the follow-up schedule; two of these patients
remained in complete remission, while one patient relapsed
at a later point. PET/CT performed after ASCT could de-
tect relapses with a positive predictive value of 0.7.
A positive PET/CT during or after completion of salvage
chemotherapy but before ASCT was associated with inferi-
or EFS (HR 2.72 (1.42–5.2), p <0.01) and OS (HR 2.65
(1.11–6.33), p <0.05) (fig. 4a, b). In addition, a positive
PET/CT performed within 3 months after ASCT also im-
pacted adversely on EFS (HR 4.74 (2.33–9.64), p <0.001)
and OS (HR 7.11 (2.76–18.34), p <0.001) (fig. 4c, d).
In the patient subgroups with DLBCL and HL, only for the
DLBCL patients a positive PET/CT before and after ASCT
was associated with reduced EFS (both p <0.05), but not
OS. No differences were observed for HL patients regard-
ing PET/CT before ASCT. An analysis of the HL patient
subgroup which had received PET/CT after ASCT was not
possible due to the low number of events (figs 5 and 6).
Risk factor analysis
In a univariate Cox proportional hazards analysis in pa-
tients with DLBCL and HL, initial stage, the number of
previous chemotherapy lines, PET results and patient age
were adverse risk factors for EFS. Initial stage, number of
previous treatment lines, PET results, patient age, grade 4
thrombocytopenia, and number of RBC and platelet units
transfused were adverse prognostic factors for OS (table 4).
Due to the generally favourable outcomes in our patients
and the low number of events a multivariate analysis could
only be performed for EFS, which identified initial lymph-
oma stage and number of previous treatment lines as inde-
pendent risk factors (table 5).
Discussion
To identify risk factors for overall and event-free survival
we evaluated the outcome data of our NHL and HL patients
treated with ASCT. The number of previous chemotherapy
lines, the responsiveness to first line chemotherapy, the
Table 3: Conditioning regimens used according to lymphoma subtype.
BEAM CBV Other
Hodgkin’s lymphoma – n (%) 22 (48) 24 (52) 0 (0)
Non-Hodgkin‘s lymphoma – n (%)
– Low-grade lymphoma
– DLBCL
– Mantle cell lymphoma
– T-cell lymphoma
– Other
11 (55)
30 (51)
21 (84)
17 (68)
2 (40)
8 (40)
27 (46)
4 (16)
8 (32)
1 (20)
1 (5)
2(3)
0 (0)
0 (0)
2 (40)
BEAM = carmustine, etoposide, cytarabine and melphalan; CBV = cyclophosphamide, carmustine and etoposide; DLBCL = diffuse large B cell lymphoma.
Table 4: Prognostic factors for event free and overall survival by univariate Cox proportional hazards analysis in diffuse large B cell lymphoma and Hodgkin’s lymphoma
patients.
Event free survival Overall survivalParameter
HR Lower 95
CI
Upper
95 CI
p-value HR Lower 95
CI
Upper 95
CI
p-value
Observations
Available
(total = 105)
CD34+ cells mobilised (≥3 vs <3 x 106/kg)
Previous irradiation (yes vs no)
Patient age (per year)
Response before ASCT (<CR vs CR(u))
CR less than 12 months (yes vs no)
Initial lymphoma stage (III-IV vs I-II)
Platelet transfusions (per unit)
RBC transfusions (per unit)
Duration of grade 4 neutropenia (per day)
Duration of grade 4 thrombopenia (per day)
Number of previous lines (≥3 vs <3)
PET positive before ASCT (yes vs no)
0.58
0.83
1.02
1.81
1.34
2.84
1.06
1.06
0.97
1.07
2.15
2.47
0.31
0.46
1.00
0.83
0.72
1.5
0.94
0.95
0.81
0.98
1.14
1.13
1.09
1.49
1.04
3.93
2.47
5.37
1.19
1.18
1.17
1.16
4.07
5.4
0.09
0.53
0.04
0.13
0.35
0.001
0.36
0.29
0.77
0.12
0.02
0.02
0.59
0.84
1.04
3.05
1.81
2.41
1.15
1.15
1.08
1.13
2.82
3.33
0.27
0.4
1.01
0.91
0.79
1.08
1.00
1.02
0.88
1.03
1.31
1.13
1.29
1.78
1.06
10.23
4.12
5.37
1.32
1.29
1.32
1.23
6.06
9.77
0.18
0.66
0.01
0.06
0.15
0.026
0.048
0.03
0.49
0.01
0.01
0.02
105
105
105
102
105
104
104
104
105
101
104
65
HR = hazard ratio; CI = confidence interval; ASCT = autologous stem cell transplantation; CR = complete response; PET = positron emission tomography.
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initial lymphoma stage and the PET/CT-status before and
after transplantation could be identified as important risk
factors.
Other factors with an impact on survival were an increased
need for RBC and platelet unit transfusions, as well as the
duration of grade 4 thrombocytopenia.
Patient selection criteria as well as the treatment underwent
a practice change during the last ten years at our institution.
Figure 4
Impact of pre- and post-transplantation PET/CT on event free
survival (A, C) and overall survival (B, D) in all patients. Pre-
transplantation PET/CT was done during or after induction
chemotherapy, post-transplantation PET/CT was done within 3
months after ASCT.
Figure 5
Impact of pre-transplantation PET/CT on event free and overall
survival according to lymphoma entity. Hodgkin’s lymphoma (A, B)
and DLBCL (C, D).
Until 2005, patients received predominantly CBV as con-
ditioning regimen, but from 2006 on BEAM was the pre-
ferred regimen due to its more favourable toxicity profile
[18–20]. As a result of the optimisation of the transplant
procedure and the supportive care measures, the indication
for ASCT was continuously expanded, especially in pa-
tients suffering from DLBCL. As a consequence, older pa-
tients with more advanced DLBCL were increasingly se-
lected for autotransplant during the observation period. In
fact, the difference in patient age reached almost statistic-
al significance and may explain the worse survival for the
DLBCL patients who were autotransplanted from 2006 on.
Another factor that may have impacted negatively on pa-
tient outcome in our study is the prior exposure to ritux-
imab, since only a few patients had been pre-treated in the
early period and most patients had received prior ritux-
Figure 6
Impact of post-transplantation PET/CT on event free survival (A)
and overall survival (B) in DLBCL patients.
Table 5: Multivariate Cox regression model for event free survival, including statistically significant parameters from the univariate analysis.
Parameter Coef. HR = exp. (coef.) 95% CI p-value Observations available
(total = 105)
Initial lymphoma stage (III/IV vs I/II)
PET+ before ASCT (yes vs no)
Number of previous lines (≥3 vs <3)
Patient age (per year)
1.47
0.81
0.91
–0.009
4.34
2.26
2.48
0.99
[1.47, 10.81]
[1.00, 5.09]
[1.10, 5.60]
[0.96, 1.02]
0.002
0.05
0.03
0.51
104
65
104
105
HR = hazard; CI = confidence interval; PET = positron emission tomography; ASCT = autologous stem cell transplantation-
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imab in the late period. Several studies have shown that
rituximab during first line treatment was associated with
worse survival in relapsing patients [21, 22]. In summary,
the observed outcome of the patients receiving ASCT after
BEAM is comparable to the results presented in the Col-
laborative Trial in Relapsed Aggressive Lymphoma
(CORAL), confirming these data also in the daily practice
outside of a clinical trial [21]. The low mortality rates
after ASCT highlight that the impact on survival is not due
to toxicities and subsequent differences in short-term out-
come after transplantation, but rather due to patient hetero-
geneities [21, 23].
The most relevant risk factor identified in our study was
the initial lymphoma stage. This finding confirms its es-
tablished role as the main prognostic factor for patient out-
come. Accordingly, lymphoma stage nowadays is the basis
for a risk-adapted treatment decision, either directly in HL
patients, or indirectly via the IPI score in DLBCL patients
[24].
Increasing numbers of previous chemotherapy lines before
ASCT were associated with worse survival. This may be
explained by the lower chemosensitivity and more aggress-
ive course of the underlying disease, which renders it pro-
gnostically disadvantageous [25, 26]. This is also suppor-
ted by our observation that patients with primary refractory
disease had a lower survival rate than patients with relapsed
disease.
Another important finding of our analysis was the impact
of the PET/CT in the ASCT setting. A PET/CT with per-
sistent pathologic FDG-uptake during or after salvage
chemotherapy was associated with reduced EFS and OS. In
addition, a positive PET/CT within 3 months after ASCT
was also associated with a worse outcome. For the patient
subgroup with DLBCL alone, a positive PET/CT before
and after ASCT was associated with inferior EFS, but only
a trend for inferior OS was seen. For the HL patient sub-
group, no statistically meaningful differences were seen.
The lack of statistically significant differences for survival
in the subgroup analyses may be explained by the low num-
ber of events in our patient cohort, since, especially HL pa-
tients, had a very favourable long-term disease free time
and overall survival rate. Only very few HL patients had
persistent FDG-avid lesions in the PET/CT after ASCT,
thus preventing a statistically meaningful analysis. On the
other hand, one could argue, based on these data, that pa-
tients with HL benefit more from high dose therapy than
DLBCL patients, even if the lymphoma cells show resid-
ual FDG-uptake before transplantation. A few other stud-
ies have reported on the impact of PET positivity before
[27–32] and after [33, 34] ASCT in lymphoma patients,
and are in line with our findings. We hypothesise, based
on these results that pre- and post-transplantation PET/CT
may be a useful prognostic marker for lymphoma patients.
In our risk factor analysis we found a correlation of in-
creased requirement for RBC and platelet unit transfusions
(and length of grade 4 thrombocytopenia, respectively)
with survival. Transfusion of RBC or platelets was an ad-
verse risk factor for OS, but not EFS. Interestingly, an in-
creased need for RBC transfusions has also been linked
to adverse outcome in patients undergoing cardiac surgery
or surgery for hip fracture [35–37]. In the ASCT setting
of lymphoma patients, the presence of anaemia has been
identified as an independent risk factor for survival [38],
but the influence of the number of blood product transfu-
sions on the long-term outcome has not been broadly re-
ported. It is not clear, however, whether the increased need
for blood products correlates with an increased long-term
risk of death due to immunomodulation or induction of
chronic inflammatory events, or whether it is just reflect-
ing a prognostically unfavourable, more severely ill patient
subgroup with reduced bone marrow function in need for
transfusions.
The main limitations of our study are its retrospective
nature and the limited patient number. Retrospective eval-
uation of data is often hindered by missing or inadequate
documentation. However, most of the individual data have
been originally coded prospectively, and we are reporting
on all consecutive patients transplanted during the evalu-
ated time period, thus avoiding any form of selection bias.
Another limitation may be that our patients came from one
area of Switzerland and the results may therefore not be
generalisable to the whole of Switzerland and other coun-
tries. Finally, since many patients had been initially pre-
treated at other hospitals and the treatment had not been
predefined, differences in first line chemotherapy regimens
may have influenced the subsequent response to ASCT and
consequently the survival rates.
In conclusion, the long-term survival data of our patients
with HL and NHL are in agreement with the existing liter-
ature indicating treatment with international quality stand-
ards. Both CBV and BEAM are effective conditioning regi-
mens for lymphoma patients. Most importantly, we present
an out-of-study confirmation of the recently published
CORAL data by demonstrating similar efficacy of BEAM
as conditioning regimen followed by ASCT in patients
with DLBCL. Responsiveness to primary chemotherapy,
initial lymphoma stage, the amount of pre-treatment, and
a PET/CT scan before and after ASCT are prognostic for
survival. Interestingly, an increased need for blood product
transfusions during the post-transplant period is associated
with a higher risk for reduced survival in our patients.
Our results may lay the foundation for further research in
wider populations before specific treatment recommenda-
tions can be finally derived.
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Figures (large format)
Figure 1
Correlation of the number of reinfused CD34+ stem cells with the length of neutropenias (r = –0.25, fig. A) and thrombocytopenias (r = –0.18,
fig. B) after ASCT.
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Figure 2
Event free survival (A) and overall survival (B) of the patients with respect to the different lymphoma subgroups.
MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin’s lymphoma; TCL, T cell lymphoma.
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Figure 3
Impact of chemosensitivity to primary chemotherapy on event free survival (A) and overall survival (B).
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Figure 4
Impact of pre- and post-transplantation PET/CT on event free survival (A, C) and overall survival (B, D) in all patients. Pre-transplantation PET/
CT was done during or after induction chemotherapy, post-transplantation PET/CT was done within 3 months after ASCT.
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Figure 5
Impact of pre-transplantation PET/CT on event free and overall survival according to lymphoma entity. Hodgkin’s lymphoma (A, B) and DLBCL
(C, D).
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Figure 6
Impact of post-transplantation PET/CT on event free survival (A) and overall survival (B) in DLBCL patients.
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